Starlake Bioscience Co Inc Zhaoqing Guangdong - Asset Resilience Ratio
Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) has an Asset Resilience Ratio of 0.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Starlake Bioscience Co Inc Zhaoqing Guan to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1995–2025)
This chart shows how Starlake Bioscience Co Inc Zhaoqing Guangdong's Asset Resilience Ratio has changed over time. See Starlake Bioscience Co Inc Zhaoqing Guan (600866) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Starlake Bioscience Co Inc Zhaoqing Guangdong's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600866 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥50.78 Million | 0.29% |
| Total Liquid Assets | CN¥50.78 Million | 0.29% |
Asset Resilience Insights
- Limited Liquidity: Starlake Bioscience Co Inc Zhaoqing Guangdong maintains only 0.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Starlake Bioscience Co Inc Zhaoqing Guangdong Industry Peers by Asset Resilience Ratio
Compare Starlake Bioscience Co Inc Zhaoqing Guangdong's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 6.52% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Annual Asset Resilience Ratio for Starlake Bioscience Co Inc Zhaoqing Guangdong (1995–2025)
The table below shows the annual Asset Resilience Ratio data for Starlake Bioscience Co Inc Zhaoqing Guangdong.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | CN¥462.07K ≈ $67.62K |
CN¥17.24 Billion ≈ $2.52 Billion |
-1.04pp |
| 2024-12-31 | 1.04% | CN¥151.05 Million ≈ $22.10 Million |
CN¥14.55 Billion ≈ $2.13 Billion |
+0.99pp |
| 2023-12-31 | 0.04% | CN¥6.41 Million ≈ $937.75K |
CN¥14.38 Billion ≈ $2.10 Billion |
-1.87pp |
| 2022-12-31 | 1.91% | CN¥306.16 Million ≈ $44.80 Million |
CN¥16.00 Billion ≈ $2.34 Billion |
+1.75pp |
| 2021-12-31 | 0.17% | CN¥4.12 Million ≈ $602.47K |
CN¥2.47 Billion ≈ $361.93 Million |
-7.14pp |
| 2016-12-31 | 7.31% | CN¥125.00 Million ≈ $18.29 Million |
CN¥1.71 Billion ≈ $250.27 Million |
+6.94pp |
| 2015-12-31 | 0.37% | CN¥6.89 Million ≈ $1.01 Million |
CN¥1.84 Billion ≈ $269.83 Million |
+0.35pp |
| 2014-12-31 | 0.02% | CN¥541.56K ≈ $79.25K |
CN¥2.26 Billion ≈ $330.05 Million |
-0.63pp |
| 2013-12-31 | 0.65% | CN¥16.96 Million ≈ $2.48 Million |
CN¥2.60 Billion ≈ $381.01 Million |
+0.64pp |
| 2012-12-31 | 0.01% | CN¥381.68K ≈ $55.85K |
CN¥3.33 Billion ≈ $487.67 Million |
-0.01pp |
| 2011-12-31 | 0.02% | CN¥774.46K ≈ $113.33K |
CN¥3.42 Billion ≈ $500.81 Million |
+0.02pp |
| 2009-12-31 | 0.00% | CN¥35.50K ≈ $5.19K |
CN¥1.50 Billion ≈ $219.15 Million |
-0.02pp |
| 2005-12-31 | 0.02% | CN¥289.32K ≈ $42.34K |
CN¥1.36 Billion ≈ $199.66 Million |
+0.00pp |
| 2004-12-31 | 0.02% | CN¥265.71K ≈ $38.88K |
CN¥1.30 Billion ≈ $190.85 Million |
-0.04pp |
| 2003-12-31 | 0.06% | CN¥700.24K ≈ $102.47K |
CN¥1.17 Billion ≈ $171.41 Million |
-1.50pp |
| 2002-12-31 | 1.56% | CN¥15.93 Million ≈ $2.33 Million |
CN¥1.02 Billion ≈ $149.82 Million |
-1.00pp |
| 2001-12-31 | 2.55% | CN¥25.59 Million ≈ $3.74 Million |
CN¥1.00 Billion ≈ $146.56 Million |
+2.50pp |
| 1999-12-31 | 0.06% | CN¥500.00K ≈ $73.17K |
CN¥847.38 Million ≈ $124.00 Million |
+0.05pp |
| 1997-12-31 | 0.01% | CN¥26.00K ≈ $3.80K |
CN¥510.92 Million ≈ $74.76 Million |
0.00pp |
| 1996-12-31 | 0.01% | CN¥26.00K ≈ $3.80K |
CN¥385.33 Million ≈ $56.39 Million |
-0.01pp |
| 1995-12-31 | 0.01% | CN¥51.53K ≈ $7.54K |
CN¥359.32 Million ≈ $52.58 Million |
-- |
About Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an interme… Read more